PubMed (MeSH Keyword) for id: 25257557

Year	Number of Results
2010	1
2011	1
2012	1
2013	2
2014	5
2015	5
2016	11
2017	9
2018	14
2019	8
2020	9
2021	11
2022	9
2023	5
2024	2

1

Extraordinary collateral mutagenesis induced by CX-5461.

Boulton SJ. Boulton SJ. Nat Genet. 2024 Jan;56(1):12-13. doi: 10.1038/s41588-023-01611-8. Nat Genet. 2024. PMID: 38129540 No abstract available.

2

Effects of the G-quadruplex-binding drugs quarfloxin and CX-5461 on the malaria parasite Plasmodium falciparum.

Craven HM, Nettesheim G, Cicuta P, Blagborough AM, Merrick CJ. Craven HM, et al. Int J Parasitol Drugs Drug Resist. 2023 Dec;23:106-119. doi: 10.1016/j.ijpddr.2023.11.007. Epub 2023 Nov 24. Int J Parasitol Drugs Drug Resist. 2023. PMID: 38041930 Free PMC article.

3

The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.

Koh GCC, Boushaki S, Zhao SJ, Pregnall AM, Sadiyah F, Badja C, Memari Y, Georgakopoulos-Soares I, Nik-Zainal S. Koh GCC, et al. Nat Genet. 2024 Jan;56(1):23-26. doi: 10.1038/s41588-023-01602-9. Epub 2023 Nov 30. Nat Genet. 2024. PMID: 38036782 Free PMC article.

4

A synthetic lethal approach to drug targeting of G-quadruplexes based on CX-5461.

Jin M, Hurley LH, Xu H. Jin M, et al. Bioorg Med Chem Lett. 2023 Jul 15;91:129384. doi: 10.1016/j.bmcl.2023.129384. Epub 2023 Jun 18. Bioorg Med Chem Lett. 2023. PMID: 37339720

5

A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer.

Chung SY, Chang YC, Hsu DS, Hung YC, Lu ML, Hung YP, Chiang NJ, Yeh CN, Hsiao M, Soong J, Su Y, Chen MH. Chung SY, et al. Neoplasia. 2023 Jan;35:100856. doi: 10.1016/j.neo.2022.100856. Epub 2022 Nov 25. Neoplasia. 2023. PMID: 36442297 Free PMC article.

6

A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex).

Xu H, Hurley LH. Xu H, et al. Bioorg Med Chem Lett. 2022 Dec 1;77:129016. doi: 10.1016/j.bmcl.2022.129016. Epub 2022 Oct 3. Bioorg Med Chem Lett. 2022. PMID: 36195286 Review.

7

Novel RNA polymerase I inhibitor CX-5461 suppresses imiquimod-induced experimental psoriasis.

Wu X, Yin Q, Wang J, Dai C, Wang J, Guo X, Jiang F. Wu X, et al. Exp Dermatol. 2023 Jan;32(1):91-99. doi: 10.1111/exd.14682. Epub 2022 Oct 7. Exp Dermatol. 2023. PMID: 36168732

8

CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response.

Snyers L, Laffer S, Löhnert R, Weipoltshammer K, Schöfer C. Snyers L, et al. Sci Rep. 2022 Aug 17;12(1):13972. doi: 10.1038/s41598-022-17923-4. Sci Rep. 2022. PMID: 35978024 Free PMC article.

9

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.

Hilton J, Gelmon K, Bedard PL, Tu D, Xu H, Tinker AV, Goodwin R, Laurie SA, Jonker D, Hansen AR, Veitch ZW, Renouf DJ, Hagerman L, Lui H, Chen B, Kellar D, Li I, Lee SE, Kono T, Cheng BYC, Yap D, Lai D, Beatty S, Soong J, Pritchard KI, Soria-Bretones I, Chen E, Feilotter H, Rushton M, Seymour L, Aparicio S, Cescon DW. Hilton J, et al. Nat Commun. 2022 Jun 24;13(1):3607. doi: 10.1038/s41467-022-31199-2. Nat Commun. 2022. PMID: 35750695 Free PMC article.

10

CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I.

Lehman SL, Schwartz KR, Maheshwari S, Camphausen K, Tofilon PJ. Lehman SL, et al. Sci Rep. 2022 Mar 8;12(1):4059. doi: 10.1038/s41598-022-07928-4. Sci Rep. 2022. PMID: 35260696 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

80 results

Results by year